Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets recall — FDA D-0259-2026
Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Overview of recall records associated with Alvogen, Inc., including dates, categories and classifications where available.
Classification mix: Class II: 3, Class I: 2, Class III: 1.
Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.
Sub-Potent Drug: Out of specification for assay at the 24 month interval.
Product Mix-Up: Customer complaint that their carton labeled as Fentanyl Transdermal Systems, 12 mcg/h contained five patches labeled and containing 50 mcg/h.
Cross Contamination with another product:residual powder found in inlet air duct identified as sorafenib
Failed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the oxycodone component.
This page summarizes recall records in which the official source identifies Alvogen, Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.